A r t i c l e s T cells can be directed to target tumor cells through expression of a CAR. CARs are synthetic receptors consisting of an extracellular antigen recognition domain, which is most commonly a scFv, but can also take the form of any antigen-binding peptide. This binding domain is then linked, with or without a hinge domain, to intracellular T cell activation and co-stimulation domains. Although CAR-T cell therapy has shown notable results in patients with B-cell acute lymphoblastic leukemia 1 , its efficacy in treating other hematological and solid tumors has been less impressive 1 .
These modest responses may relate to the tumor microenvironment (TME). When infused into patients, CAR-T cells often encounter an inhibitory TME, with cells and inhibitory ligands that can bind to inhibitory receptors on T cells and hinder T cell anti-tumor responses. For instance, in ovarian cancer, immunosuppressive M2-polarized tumor-associated macrophages (TAMs) 2 and regulatory T (Treg) cells 3, 4 have been found to populate the TME, and the presence of these cells correlates with reduced tumor-infiltrating lymphocytes 5 and poor outcomes in patients 2, 3 . Both TAMs and Treg cells suppress infiltrating T cells via contact-and cytokine-mediated mechanisms 5, 6 . Furthermore, following activation, T cells secrete IFN-γ, an effector cytokine, which has been shown to dynamically upregulate programmed death ligand-1 (PD-L1) expression on ovarian cancer cells in both clinical 7 and preclinical models 8 . PD-L1 binds to the inhibitory receptor programmed death 1 (PD-1) on T cells and suppresses T cell function 9 . Interruption of PD-1/PD-L1 ligation via CRISPR-mediated deletion of PD-L1 on ovarian cancer cells improved the efficacy of adoptively transferred second-generation CAR-T cells in preclinical models 8 . These factors may contribute to the lack of clinical efficacy of CAR-T cells for this solid tumor malignancy 10 .
Checkpoint blockade therapy, which uses antibodies to disrupt the interaction between inhibitory receptors on T cells, particularly CTLA-4 and PD-1, and their suppressive ligands on tumors cells, has yielded clinical responses in patients with a range of solid tumors [11] [12] [13] and hematological malignancies 14 . Correlates for the efficacy of checkpoint blockade therapy include T cell activation markers, tumor cell expression of PD-L1, a pre-existing CD8 + T cell infiltrate in the tumor 15, 16 and tumor mutational burden 15, [17] [18] [19] [20] . Together, these results suggest that tumor-specific T cells are an integral mechanism of action of checkpoint blockade and that re-engagement of pre-existing tumorspecific T cells is critical to the success of this therapeutic modality.
We have previously described 'armored' CAR-T cells, which are CAR-T cells that are co-modified to express immunomodulatory ligands such as CD40L 21 or to secrete cytokines such as IL- 12 (refs. 8,22-25) or IL-18 (ref. 26 ) to enhance CAR-T cell function in the tumor microenvironment. Based on our previous findings, rather than combining CAR-T cells with existing systemic checkpoint blockade antibody treatment, as studied previously in preclinical models 8, 27, 28 , we sought to use our armored CAR-T cell platform to create a single therapy in which CAR-T cells secrete an immune checkpoint blockade scFv. Given that CAR-T cells traffic to the tumor, the PD-1-blocking targeted delivery of a PD-1-blocking scFv by cAr-t cells enhances anti-tumor efficacy in vivo A r t i c l e s scFvs would be delivered locally to the site of disease, thereby minimizing the toxicities associated with immune checkpoint blockade. We found that CAR-T cells that secreted a PD-1-blocking scFv enhanced the survival of PD-L1 + tumor-bearing mice in syngeneic and xenogeneic mouse models through both autocrine and paracrine mechanisms. This strategy has the potential to enhance the efficacy of CAR-T cell therapy in cancers with an immune-suppressive TME.
RESULTS
Modification of mouse CAR-T cells to secrete an anti-mouse PD-1-blocking scFv To test our approach in an immunocompetent syngeneic mouse model, we generated retroviral second-generation CAR constructs containing binding domains that recognize CD19 or the retained portion of MUC16 (MUC16 ecto ) 29 and mouse CD28 and CD3 zeta T cell signaling domain. These conventional CARs were labeled 19m28mZ or 4H11m28mZ, respectively. Armored mouse CAR constructs, labeled 19m28mZ/RMP1-14 or 4H11m28mZ/RMP1-14, used the same backbone, binding domain and mouse signaling domain as the second-generation mouse CAR and were also co-modified to include a c-myc-tagged scFv derived from variable heavy and light chains from the anti-mouse PD-1-blocking monoclonal antibody (mAb), RMP1-14 (ref. 30 ; Fig. 1a ). We transduced primary mouse T cells to express the CAR constructs ( Fig. 1b) and secrete RMP1-14 scFvs (25.6 kDa; Fig. 1c and Supplementary Fig. 1a) .
We co-cultured scFv-secreting CAR-T cells with human CD19expressing mouse lymphoma EL4 cells (hCD19 mPD-L1) or MUC16 ecto -expressing ovarian tumor ID8 cells, which upregulate PD-L1 after exposure to IFN-γ ( Fig. 1d) . Conventional and RMP1-14 scFv-secreting CAR-T cells specifically lysed ( Fig. 1e) and produced IFN-γ ( Fig. 1f ) when cultured with tumor targets.
We next evaluated the binding of secreted RMP1-14 scFvs to PD-1. There was a significant decrease in the amount of surface PD-1 on 19m28mZ/RMP1-14 T cells compared with cells modified to express 19m28mZ (P = 0.01), consistent with the scFvs binding in an autocrine manner to secreting CAR-T cells ( Fig. 1g and Supplementary  Fig. 1b ). To determine whether scFvs bind to bystander PD-1 expressing cells, we co-cultured 4H11m28mZ T cells in the bottom well of a transwell plate with either 19m28mZ or 19m28mZ/RMP1-14 cells on top. After 24 h, we detected lower levels of PD-1 on the surface of 4H11m28mZ cells cultured with 19m28mZ/RMP1-14 cells than on those cultured with 19m28mZ T cells (P = 0.04; Fig. 1h ), consistent with the binding of secreted scFvs to bystander cells.
PD-1-blocking scFvs are secreted by CAR-T cells in vivo
We next validated the presence of PD-1-blocking scFvs secreted by CAR-T cells in the TME. Tumor-bearing mice with palpable ascites were injected intraperitoneally (i.p.). with CAR-T cells ( Fig. 2a) . Ascites from these mice was harvested 48 h later and RMP1-14 scFvs secreted from 4H11m28mZ/RMP1-14 T cells was detected by immunoprecipitation with an anti-myc-tag antibody and western blot analysis ( Fig. 2b and Supplementary Fig. 2) , as well as by anti-myc-tag Luminex (P = 0.0004; Fig. 2c ).
We next tested the efficacy of scFv-secreting CAR-T cells in a syngeneic, immune-competent mouse model of metastatic ovarian carcinoma. C57BL/6 mice were injected i.p. with ID8 cells and treated 7 d later with CAR-T cells. 4H11m28mZ/RMP1-14 T cells showed enhanced survival as compared with mice treated with 4H11m28mZ (P = 0.004) and 19m28mZ/RMP1-14 T cell controls (P = 0.0006). Treatment with 4H11m28mZ/RMP1-14 T cells or 4H11m28mZ T cells + RMP1-14 antibody revealed a comparable survival benefit (P = 0.051; Fig. 2d ). Tumor-bearing mice treated with RMP1-14 mAb alone had no survival benefit over mice treated with control CAR-T cells.
PD-1 binding to PD-L1 can result in T cell exhaustion, anergy and/ or apoptosis. We found that long-term surviving mice treated with 4H11m28mZ/RMP1-14 T cells or 4H11m28mZ T cells + RMP1-14 antibody had detectable CAR-T cells by PCR in the bone marrow over 120 d post-tumor inoculation ( Fig. 2e ). In addition, 4H11m28mZ/ RMP1-14 treated mice were able to mount an anti-tumor response when re-challenged with the initial dose of ID8 tumor cells (P < 0.0001; Fig. 2f ), as compared with naive untreated mice.
We hypothesized that CAR-T cells secreting PD-1-blocking scFvs could re-invigorate endogenous tumor-specific T cells. To test this, we injected C57BL/6 mice subcutaneously (s.c.) with the immunogenic melanoma cell line B16-F10. These mice mount an endogenous response to the tumor but cannot eradicate it 30 . Endogenous bystander tumor-infiltrating lymphocytes isolated from mice treated intratumorally with 4H11m28mZ/RMP1-14 CAR-T cells expressed significantly higher levels of CD80, CD107α, IFN-γ and granzyme B than those treated with 4H11m28mZ (P < 0.05; Fig. 2g and Supplementary Fig. 3 ).
Selection of human PD-1-blocking scFv E27
The human PD-1-blocking scFvs E23, E26 and E27 were isolated from a human scFv phage display library (Eureka Therapeutics). The dissociation constants (K D ) for the three lead candidates, E23, E26 and E27, binding to PD-1 were 8.3, 6.3 and 3.6 nM, respectively. The E23, E26 and E27 antibodies were able to block PD-1 from binding to PD-L1 in a dose-dependent manner (Fig. 3a) . We collected supernatant from equivalent numbers of transduced viral producer cells and detected anti-PD1 secretable scFvs (Fig. 3b,c) . The most intense band was observed for clone E27, indicating that the scFv was the most stable in supernatant. For this reason, we used E27 in subsequent studies ( Fig. 3c and Supplementary Fig. 4a ).
Modification of human CAR-T cells to secrete an anti-human PD-1-blocking scFv
We generated human CAR constructs encoding the CD19-or MUC16 ecto -targeted CAR and the His/HA-tagged E27 scFv (1928z-E27 and 4H1128z-E27, respectively; Fig. 3d ). Transduced T cells expressed CAR on the surface ( Fig. 3e ) and secreted E27 scFv ( Fig. 3f and Supplementary Fig. 4b ). Binding of E27 to PD-1 was demonstrated by HA-tag detection on 293Glv9-PD1 + cells after incubation in supernatant from 1928z-E27 T cells ( Fig. 3g and Supplementary Fig. 4c ). Furthermore, we detected less PD-1 on 1928z-E27 and 4H1128z-E27 T cells than on cells modified to express 1928z or 4H1128z, consistent with the binding of E27 scFv to T cell PD-1 ( Fig. 3h and Supplementary Fig. 4d ). We corroborated antigen-dependent lysis by CAR-T cells in the context of tumor cells ( Fig. 3i) .
We transduced Raji and NALM6 tumor cells to express PD-L1 and co-cultured 1928z and 1928z-E27 T with either Raji-PD-L1 or NALM6-PD-L1 tumor at 1:1 tumor:CAR-T cell ratio. After 72 h of coculture, we used flow cytometry to detect the remaining tumor cells. 1928z-E27 T cells lysed more Raji-PDL1 and NALM6-PDL1 tumor cells than 1928z T cells. (Fig. 4a,b ). Using this assay, we found increased expansion of 1928z-E27 T cells following co-culture with Raji-PDL1 or NALM-PDL1 tumor compared with 1928z T cells ( Fig. 4c) , consistent with 1928z-E27 T cell response to PD-L1-mediated suppression. Following co-culture with Raji-PD-L1, 1928z-E27 cells showed lower levels of surface PD-1 detection than 1928z T cells, as determined by both the percentage of positive cells and the mean fluorescence intensity of the staining (Fig. 4d,e) . A r t i c l e s E27 binds to bystander cells To demonstrate that untransduced bystander cells can benefit from the E27 scFv secreted from nearby CAR-T cells, we first cocultured healthy human donor T cells with 1928z or 1928z-E27 CAR-T cells and stimulated the cells with anti-CD3 and anti-CD28 beads. After 4 d of co-culture, CAR + and CAR − T cells were sorted and western blot analysis demonstrated E27 binding to PD-1 on both CAR + and CAR − cells in the 1928z-E27/PD-1 T cell co-culture, but not the 1928z/PD-1 T-cell co-culture ( Fig. 4f and Supplementary Fig. 5 ).
We cultured 1928z and 1928z-E27 T cells with 3T3-empty or 3T3-PDL1 cells and stimulated them with anti-CD3 and anti-CD28 beads. A r t i c l e s 1928z T cells that were cultured with 3T3-empty cells showed enhanced proliferation compared with 1928z T cells cultured with 3T3-PDL1 cells (Fig. 4g,h) . However, 1928z-E27 T cells showed similar expansion when cultured with 3T3-empty and 3T3-PDL1 cells (Fig. 4h) .
There was no significant difference between the expansion of 1928z and 1928z-E27 T cells when cultured with 3T3-empty cells (P = 0.063; Fig. 4h ).
By day 12, 1928z T cells cultured with 3T3-PDL1 cells had significantly decreased cell numbers compared with those cultured with 3T3-empty cells. We anticipated that the population of CAR + and CAR − cells would contract in this condition in a similar ratio and that the overall CAR + percentage would remain the same relative to time 0. This is what we observed when we calculated the CAR + cells relative to time 0 ( Fig. 4i) . However, because the 1928z-E27 cells cultured with 3T3-PDL1 cells expanded substantially by day 12, it may be expected that the total number of CAR + cells would increase, thereby leading to an increased percentage of CAR + cells. This would be the case if the PD-1-blocking scFvs bestowed a select proliferative advantage only to the cell that was secreting it. However, the percentage of CAR + 1928z-E27 T cells following expansion on 3T3-PDL1 cells was not increased on day 12 compared with day 0, indicating that the E27 scFv protects the expansion of transduced T cells as well as untransduced bystander cells in the context of PD-L1 ( Fig. 4i) .
CAR-T cells secreting E27 scFv have enhanced anti-tumor function in vivo
We determined the in vivo anti-tumor efficacy of E27-secreting CAR-T cells by inoculating SCID/Beige mice with Raji-PDL1 or NALM6-PDL1 tumor cells intravenously (i.v.). Infusion of 1928z-E27 T cells significantly enhanced the survival of both Raji-PDL1 (P = 0.03; Fig. 5a ) and NALM6-PDL1 (P = 0.01; Fig. 5b ) tumor-bearing mice compared with an infusion of 1928z T cells.
Next, we investigated the anti-tumor efficacy of E27-secreting CAR-T cells in a solid tumor model of peritoneal carcinomatosis. SKOV3-PDL1 tumor-bearing SCID/Beige mice treated with 4H1128z-E27 T cells showed enhanced survival compared with mice treated with 4H1128z T cells (P = 0.02; Fig. 5c ). In addition, using this preclinical xenograft model of metastatic ovarian tumor, mice treated with E27 scFv-secreting 4H1128z T cells had enhanced survival benefit over mice treated with 4H1128z T cells + anti-human PD-1 mAb (P = 0.048; Fig. 5d ).
To demonstrate in vivo the bystander effect of the E27-secreting CAR-T cells, we treated SKOV3-PD-L1-bearing mice with a combination of antigen-irrelevant 1928z-E27 and tumor-specific 4H1128z CAR-T cells. In this experimental model, only the antigen-irrelevant CAR-T cells expressed the PD-1-blocking scFvs, and treatment with 1928z-E27 T cells alone had no survival benefit ( Fig. 5e,f) . However, when injected together, 1928z-E27 enhanced the anti-tumor function of second-generation 4H1128z cells, as compared with mice treated with just 4H1128z T cells (P = 0.03; Fig. 5f ). This result suggests that the E27 scFv secreted by the 1928z-E27 cells binds to bystander tumor-specific cells in vivo.
E27 scFv secreted by CAR-T cells is only detected in the local TME
Using the SKOV3 solid tumor model of peritoneal carcinomatosis, we sought to determine the local and systemic levels of CAR-secreted scFvs. First, we used in vivo bioluminescence and fluorescence imaging to visualize the location of scFv or mAb, when administered i.p., over time. CAR constructs were generated with E27 scFv fused to Gaussia Luciferase (GLuc) enzyme, an ATP-independent signal that allows the imaging of E27 location in vivo after being produced by CAR-T cells 31 . We conjugated a commercial anti-human PD-1 mAb to VivoTag 680 XL fluorochrome. CAR-T cells secreting E27-GLuc or CAR-T cells and fluorescently labeled mAb were i.p. injected into tumor-bearing mice and imaged over time (Fig. 6a) . In as early as 3 h, the antibody could be found systemically in the mice, whereas the scFv was only detected in the peritoneal cavity. Following quantification, we did not observe a difference between whole body and local amounts of E27, as E27 remained localized at the tumor site. However, we found changes in the levels of the labeled commercial antibody, as it appeared to circulate out of the tumor area ( Fig. 6b) .
To further quantify the systemic levels of antibody or scFv over time, we used targeted mass spectrometry on a high-resolution quadrupole orbitrap instrument (Supplementary Fig. 6 ). We injected SCID/Beige mice i.p. with ovarian SKOV3 tumor cells and then i.p. injected them 7 d later with E27-secreting CAR-T cells or antibody and CAR-T cells. We harvested serum samples over time and carried out targeted parallel reaction monitoring spectrometry to quantify the amounts of E27 or commercial antibody over time. Two unique tryptic peptides from the complementarity-determining regions of the scFv and mAb that are not present in other mouse or human proteins were used. Commercial PD-1-blocking mAb was detected systemically in the serum and decreased over time, as expected ( Fig. 6c) . However, we did not detect E27 in the serum at any time point, indicating that it remained localized in the TME. A control sample consisting of isolated scFv was injected i.v. to demonstrate that our assay was capable of detecting E27 in the peripheral serum. It is important to note that the stability and half-life of an antibody and a scFv molecule differ, and this may affect our ability to detect scFv in serum. However, considering that we found that the scFv could be detected 30 min after systemic infusion ( Fig. 6c) and that, in our system, the scFv is being produced constitutively by CAR T-cells in vivo, we should be able to detect CAR-T-cell-derived E27 if it is present in the periphery. Moreover, if the stability and half-life of the scFv does not allow it to leave the local TME and be detected in the periphery, this furthers our hypothesis that local checkpoint blockade using a scFv may be a safer alternative to antibodies. These results demonstrate that, unlike checkpoint blockade mAb, E27 secreted by CAR-T cells is not present systemically.
DISCUSSION
Using multiple in vivo models, we demonstrated that CAR-T cells that secrete PD-1-blocking scFv enhance the survival of mice in syngeneic and preclinical xenogeneic hematologic and solid tumor models. CAR-T cells that secrete PD-1-blocking scFv were equally effective or superior to therapy with CAR-T cells and PD-1-blocking mAb, indicating that localized delivery of PD-1 blockade is effective at enhancing CAR-T cell anti-tumor function. PD-1 blockade on CAR-T cells results in long-term surviving mice that have detectable CAR-T cells in the bone marrow and can mount an anti-tumor response when re-challenged with tumor. PD-1-blocking scFv produced by CAR-T cells can enhance the function of tumor-specific bystander T cells in vivo in the TME. Finally, unlike systemic checkpoint blockade therapy, scFvs secreted by CAR-T cells remain locally in the TME.
Preclinical studies have previously demonstrated that CAR-T cells are susceptible to suppressed effector function mediated through the PD-1 receptor and subsequent combination with PD-1/PDL-1-blocking antibodies, given exogenously or produced by CAR-T cells, results in enhanced CAR-T-cell-mediated anti-tumor response 32, 33 . However, these studies were limited to xenograft models that do not recapitulate the endogenous immunosuppressive TME, and bystander effects or A r t i c l e s localized delivery of antibody were not demonstrated. Specifically, a previous study 32 used CAR-T cells secreting an antibody (not scFv) and did not compare this to antibody alone or CAR-T cells and systemic antibody; as such, whether their approach is superior to established therapies is not clear. ScFvs are smaller, less stable molecules than antibodies and successful checkpoint blockade had not been demonstrated with them. Furthermore, the smaller size of scFvs enables the engineering of CAR constructs that are smaller, allowing for the possibility of tri-cistronic vectors with a combination of scFvs in the future. Alternative methods to prevent PD-1-related dampening of CAR-T cell responses include coexpression of a chimeric switch receptor 33 , with the extracellular domain of PD-1 being linked to activation signaling domains 34 , or co-modifying CAR-T cells to express a dominant negative PD-1 receptor 35 . Both of these methods have been shown to increase the levels of cytolysis, cytokine secretion and enhanced in vivo anti-tumor efficacy in response to PD-L1 + tumor targets compared with T cells expressing a CAR alone. However, this protective effect is limited to the CAR-T cells themselves. Endogenous tumor-infiltrating lymphocytes in the TME are still subject to PD-1-mediated suppression. Given that the PD-1-blocking scFvs secreted by CAR-T cells are able to bind to bystander cells, we hypothesize that local secretion of the PD-1-blocking scFvs described here may protect endogenous anti-tumor immune cells and reduce outgrowth of antigen-negative tumors.
Systemic administration of checkpoint blockade can result in immune-related adverse events (IRAEs) 36 . IRAEs are frequent in patients treated with checkpoint blockade 11, 13, 36 . Given that CAR-T cells traffic to and expand at the site of tumor, delivery of the PD-1-blocking scFvs was primarily localized to this area in our models. Thus, we hypothesize that our strategy, demonstrating localized and not systemic delivery, may decrease the IRAEs associated with systemic checkpoint blockade. 
A r t i c l e s
Our results validate the idea that CAR-T cells can be used to deliver immune modulatory scFvs to the TME in the absence of systemic blockade. With the rapid development of human phage display libraries, it is feasible to expand this immune-modulating CAR-T cell approach by using scFvs targeting other molecules, such as LAG-3 (refs. 37,38), TIM-3 (ref. 39) or CLTA-4 (ref. 40) , as well as combination strategies. Armored CAR-T cells for targeted delivery of immune modulatory scFvs to the TME may improve clinical outcomes of CAR T cell and checkpoint blockade therapies.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
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ONLINE METhODS
Selection of PD-1-blocking scFv. The RMP1-14 scFv was engineered from the RMP1-14 hybridoma. The PD-1-blocking scFv, termed E27, was identified from a human antibody scFv phage library (Eureka Therapeutics). The scFv library was screened for binding to human PD-1. Briefly, biotinylated PD-1-Fc fusion protein was mixed with the human scFv phage library. The antigen-scFv complexes were pulled down by streptavidin-conjugated beads and bound clones were eluted and transformed into bacteria. The binding and affinity of scFv to PD-1 was determined using ForteBio Octet QK (Pall Life Sciences). The ability of the scFv to block PD-1 from interacting with PD-L1 was determined using an ELISA assay. Briefly, PDL1-Fc (R&D Systems), was loaded onto a plate. PD-1-Fc was mixed with dilutions of antibody derived from the E27 scFv clones or human IgG1 isotype control mAb (Eureka Therapeutics) and then added to the PDL1-Fc-coated plate. Binding of the clones was determined by a standard ELISA method against biotinylated PD-1. Streptavidinconjugated HRP (Vector Laboratories) was used to detect binding on an Epoch-2 microplate reader (BioTek Instruments).
Generation of retroviral vectors. The RMP1-14 scFv was cloned into the SFG gammaretroviral vector encoding CD19-directed or MUC16 ecto -directed CARs with mouse signaling domains. The E27 scFv was cloned into the SFGretroviral vector encoding the CD19-targeted CAR, termed 1928z, to generate SFG-1928z-E27 or DNA encoding the MUC16 ecto -targeted CAR and E27 scFv, termed SFG-4H1128z-E27.
Cell culture. Retroviral producer cells were maintained in DMEM and human T cells were maintained in RPMI-1640 medium. Tumor cells and mouse T cells were maintained in RMPI-1640 medium supplemented with nonessential amino acids, sodium pyruvate, HEPES (N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid) buffer, and 2-Mercaptoethanol (all from Invitrogen). All media was supplemented with 10% FBS (Atlanta Biological Flowery Branch), 2 mM l-glutamine, 100 IU/ml penicillin and 100 µg/ml streptomycin (Invitrogen). Retroviral producer cell lines were generated by using CaPO 4 (Promega) to transiently transfect H29 cells with retroviral constructs encoding the CAR or the CAR and the PD-1-blocking E27scFv. Supernatant from the H29 cells was used to transduce Phoenix-ECO or 293Glv9 cells to produce stable retroviral producer cells lines. DNA encoding mouse and human PD-L1 and PD-1 was purchased (Integrated DNA Technologies) and separately cloned into the SFG retroviral backbone (SFG-hPD-L1, SFG-hPD-1). This was transiently transfected into H29 cells using CaPO 4 transfection (Promega) and the H29 supernatant was used to transduce tumor or 293Glv9 packaging cells. Tumor cells lines were sorted by FACS based on high expression of PD-L1 following staining with PE-conjugated anti-PD-L1 (BD Biosciences, clone MIH5). ID8 and SKOV3 cells were validated by karyotyping and all cells were routinely checked for mycoplasma.
T cell isolation and modification. Human T cells were activated and transduced as described previously 25 . Briefly, peripheral blood mononuclear cells (PBMCs) were isolated from healthy donor peripheral blood or leukopacks (New York Blood Center). All experiments were performed in compliance with all relevant ethical regulations and in accordance with IRB 095091. PBMCs were activated with 2 µg/ml phytohemagglutinin and 100 IU/ml of IL-2 for 2 d before transduction. Mouse T cells were mechanically isolated from spleens and activated using IL-2 and 4 µg/ml of concanavalin A (Millipore Sigma). Transduction was achieved by centrifugation of activated PBMCs and retroviral supernatant on RetroNectin-coated plates on 3 consecutive days (TakaraBio).
Flow cytometry. Flow cytometry was used to determine the transduction efficiency of transduced cells following staining with Alexa-Fluor 647 conjugated anti-idiotype antibodies that detect the CD19-targeted CAR (clone 19E3), 1928z, as well as the ovarian tumor-antigen targeted CAR (clone 22G3), 4H1128z (both generated at the Memorial Sloan Kettering Cancer Center Antibody and Bioresource Core Facility). The following antibodies were used in flow cytometry experiments: FITC conjugated anti-PD-1 (BD Biosciences, clone MIH4, Cat557860 CD279 Mouse anti-Human, FITC), anti-mouse PD-1 (BD Biosciences, clone J43, Cat561788 CD279 Hamster anti-Mouse, PE), anti-mouse PD-L1 from BD Biosciences (clone MIH5, Cat558091), Mouse Anti-Human CD19 mAb (clone SJ25-C1), FITC conjugate, CatMHCD1901 from Invitrogen and Anti-Human CD3 eFluor450, Cat48-0037-42 from eBioscience. Data from cells was collected using a Beckman Coulter Gallios flow cytometer and Kaluza 1.2 and analyzed using FlowJo vX.07 software (FlowJo).
For analysis of syngeneic bystander in vivo experiment, the following antibodies and reagents were used for flow cytometry: CD45-PE (clone 30-F11, Cat103106), CD3-APC/Cy7 (clone 17A2, Cat100222), CD80-PE (clone 16-10A1, Cat104708), IFN-γ-FITC (clone XMG1.2, Cat11-7311-41 from eBioscience), CD107a (LAMP-1)-PE-Cy7 (clone 1D4B, Cat121619), Granzyme B-FITC (clone GB11, Cat515403) and Zombie UV Fixable Viability Kit (Cat423107) were purchased from BioLegend. After 20 min incubation with Zombie UV Fixable stain at room temperature, all samples were washed with ice-cold BD FACS Buffer, and stained with the appropriate surface antibodies. Intracellular staining for IFN-γ and Granzyme B was performed according to Foxp3/Transcription Factor Staining Buffer Set (eBioscience). Data acquisition was performed on FACSCalibur (BC Biosciences) and analyzed via FlowJo. For analysis intratumoral CD3 + CAR − T cell levels were assessed with phenotypic criteria of CD45 + CD3 + CAR − , and total CD45 + cells were used as a common denominator.
Western blot analysis. Supernatant was collected and filtered from either 293Glv9 packaging cells or transduced T cells as indicated. To demonstrate E27 binding to PD-1, 293Glv9-PD1 packaging cells were incubated for 24 h in filtered supernatant from 1928z or 1928z-E27 transduced T cells. To demonstrate that E27 binds to untransduced, bystander cells, 1928z and 1928z-E27 T cells were co-cultured with human T cells transduced to overexpress PD-1, after 4 d stimulation with CD3/CD28 beads, the cells were sorted by flow cytometry following staining with 19E3 mAb to separate CAR + and CAR − cells. Supernatant or whole cell lysates was loaded onto mini protean TGX gels (BioRad) and then transferred to Immun-blot PVDF membranes (Bio-Rad). The was probed with mouse-anti-HA antibody (Cell Signaling,6E2, Cat2367S) and then goat anti-mouse HRP conjugated antibody (Millipore, GT X MS AP127 Cat6C0112) for E27. RMP1-14 was detected using a HRP-conjugated mouse-anti-myc tag antibody (Cell Signaling, Cat2040S). Detection of antibody was achieved with Pierce ECL western blot substrate (Thermo Scientific). RMP1-14 scFv co-immunoprecipitation was performed using the Peirce c-Myc Tag IP/Co-IP Kit (Thermo Scientific) according to the manufacturer's instructions and detected by western blot as described above.
NIH/3T3 expansion assay. NIH/3T3 (3T3-Empty) or NIH/3T3 cells transduced to express human PD-L1 (3T3-PDL1) were plated and transduced T cells were added and incubated for 24 h. CD3/CD28 beads (Invitrogen) were then added at a 1:2 bead:T cell ratio. Every 3 d, the T cells were moved to fresh 3T3 coated plates to ensure continuous stimulation with PD-L1. At 6 d, the T cells were debeaded before being plated on fresh 3T3 cells, and left without beads for 24 h. The cells were then re-stimulated with CD3/CD28 beads at the same ratio (second stimulation). Trypan blue exclusion was used to enumerate cells following removal from 3T3 cells.
Tumor expansion assay. Transduced T cells were co-cultured with Raji-PDL1 + eGFP + or NALM6-PDL1 + eGFP + tumor cells at 1:1 tumor:CAR + T-cell ratio. Following 72 h co-culture, flow cytometry was used to detect tumor and T cells following staining with anti-human CD19-FITC (Invitrogen). Cells were enumerated using 123 count ebeads (eBiosciences) according to the manufacturer's instructions.
In vivo experiments.
All experiments were performed in compliance with all relevant ethical regulations and in accordance with an Institutional Animal Care and Use Committee-approved protocol (protocol 00-05-065).
For syngeneic survival experiments, C57BL/6 mice (Jackson Laboratory) of 6-8 weeks were inoculated i.p. with 10 × 10 6 ID8 tumor cells and treated 7 d later with 2 × 10 6 CAR-T cells, as indicated, with or without 250 µg RMP1-14 antibody (Bio X Cell). Mice were given RMP1-14 antibody i.p. on days 7, 10 and 14 post tumor inoculation, for a total of three doses.
For syngeneic bystander experiments, 6-8-week-old female C57BL/6 mice (Jackson Lab) were injected subcutaneously with 10 6 B16-F10 mouse melanoma cells transduced to express the MUC16 cell surface antigen. On day 10 after tumor implantation, 2 × 10 6 CAR-T cells were injected intratumorally. The mice were sacrificed 48 h after T cell injection. Tumor cells were mechanically dissociated and digested in collagenase-based buffer. The samples were subsequently stained for flow cytometric analysis, as described above.
Fox Chase CB17 (CB17.Cg-Prkdc scid Lyst bg-J /Crl, SCID/Beige mice (Charles River Laboratories) of 6-8 weeks of age were inoculated i.v. with 1 × 10 6 Raji-PDL1 or NALM6-PDL1 tumor cells. The following day, mice received one systemic infusion of 1 × 10 7 CAR + T cells. For xenograft solid tumor studies, SCID/Beige mice were inoculated i.p. with 1 × 10 7 SKOV3-PDL1 cells and treated 7 d later with 5 × 10 6 total CAR + T cells, as indicated, with or without anti-human PD-1-blocking antibody (clone EH12.2H7, BioLegend). Mice were given 250 µg of antibody i.p. on days 7, 10 and 14 post tumor inoculation, for a total of three doses.
The PCR primers used to detect CAR isolated from splenocytes or bone marrow span mouse CD3 and the gamma-retroviral SFG backbone and are as follows: 5′AGAACCTAGAACCTCGCTGGAAAG 3′ and 5′GTGCATTGT ATACGCCTTCCTGGGGGT 3′.
Bioluminescent imaging of scFv-GLuc or anti-human PD-1 antibody (clone EH12.2H7, BioLegend) labeled with VivoTag 680 XL Fluorochrome (PerkinElmer) in SCID/Beige mice i.p. inoculated with SKOV3-PDL1 and treated 7 d later i.p with 5 × 10 6 scFv-secreting CAR-T cells or CAR-T cells with 250 µg of anti-human PD-1 antibody (clone EH12.2H7, BioLegend), was performed using Xenogen IVIS imaging system with Living Image software (Xenogen Biosciences). Image acquisition was done on a 25-cm field of view at medium binning level at various exposure times.
Targeted LC-MS/MS (PRM) analysis of scFv and mAb in serum.
To quantitate the levels of the E27 scFv and anti-human PD-1 mAb (clone EH12.2H7, Biolegend) proteins in serum a bioinformatics search was used to identify peptide sequences unique to the therapeutic proteins but not found in other proteins in human or mouse proteome. We then quantitated those peptides using targeted parallel reaction monitoring (PRM) on a high resolution and accurate mass quadrupole-orbitrap mass spectrometer 41 . To accomplish this goal, we first used Skyline 4.1 42 , a freely available software tool (online at http://skyline.maccosslab.org). Tryptic peptides that contained cysteine or methionine residues were excluded and peptides that were from the complementaritydetermining region of the therapeutics were prioritized. Two tryptic peptides, one from the scFv (FSGSNSGNTATLTISR, m/z = 806.8999 (M+2H) 2+ ions) and one from the anti-PD-1 mAb (FGSNLEGIPAR, m/z = 624.3226 (M+2H) 2+ ions), met our criteria and were used for subsequent analysis.
LC-MS/MS of scFv and mAb biotherapeutics.
To obtain the tandem mass spectra for the unique peptides in the biotherapeutics (m/z 806.89 and 624.32), the scFv and anti-PD-1 mAb proteins were separated by SDS/PAGE, stained with Simply Blue (Life Technologies Scientific), enzymatically digested in situ with trypsin 43 , and desalted 44 . The purified peptides were diluted to 0.1% formic acid and analyzed separately by high resolution LC-MS/MS in data dependent mode. We used a Waters NanoAcquity system (with a 100-µm inner diameter × 10-cm-long C18 column (1.7 µm BEH130; Waters) configured with a 180-µm × 2-cm trap column coupled to a Thermo Q-Exactive Plus orbitrap mass spectrometer. Trapping was performed at 15 µL/min buffer A for 1 min and elution with a 50% linear acetonitrile gradient over 120 min. MS data were collected in data dependent acquisition mode. Full scan MS1 spectra were acquired over 380-1,600 m/z at a resolution of 70,000 (m/z 400) with automatic gain control (AGC) at 3 × 10 6 ions. The top 15 most intense precursor ions were selected for HCD fragmentation performed at normalized collision energy (NCE) 25% with target ion accumulation value of 5 X 10(4). MS/MS spectra were collected with resolution of 17,500. See Supplementary  Figure 3 for MS/MS spectra.
Proteomic analysis of serum. For in solution digestion of mouse serum a previously published protocol was slightly modified 45 . Briefly, frozen serum samples were thawed on ice, 10 µL was transferred to a new tube then diluted with 40 µl 50 mM ammonium bicarbonate. 10 µl of the diluted serum was transferred to a new tube and further diluted with 190 µl ammonium bicarbonate containing 0.5% deoxycholate and 10 mM DTT then vortexed at 300 rpm at 56 °C for 60 min. The samples were cooled to room temperature then alkylated with the addition of 4 µl of 0.5 M iodoacetamide in 50 mM ammonium bicarbonate and incubated for 30 min in the dark. Sequencing grade trypsin (Promega Gold) was added 2 µg/sample then incubated at 37 °C for 18 h with gentle vortexing (300 rpm). To quench the reaction, 10 µl formic acid was added, DOC precipitated, then spun at 20,000 g for 4 min. 50 µl was removed to a clean tube then 4 µL of the digest taken into an autosampler vial and diluted with 46 µl buffer A before targeted LC-MS/MS (PRM) analysis.
The LC-MS/MS PRM analysis was performed on the identical LC-MS system as above but adjusted for PRM mode. The LC gradient was 2% to 50% B over 20 min followed by 90% B for 5 min with a 14 min equilibration at 300 nl/min. Full MS scans were performed with the following parameters: resolution: 70,000; AGC target: 3e6; maximum IT: 200 ms; scan range: 150 to 2,000 m/z. Targeted MS2 scans (PRM) were performed on m/z of 806.8999, 1117.5342, and 624.3226 with the following parameters: resolution: 17,500; AGC target: 2e5; maximum IT: 100ms; isolation window: 1.5 m/z; nce: 27; charge state: +2.
For each peptide, six singly charged y-type fragment ions near or above the precursor mass were used for the PRM assay as the signals were robust and showed no interfering background ions in the untreated plasma samples. Thermo Xcalibur version 2.2 was used to identify the presence of EH12/2H7 antibody and E27 scFv antibody. Chromatographic peaks of EH12/2H7 peptide (FSGSNSGNTALLTISR) and E27 scFv peptide (FGSNLESGIPAR) were identified by searching (M+2H) 2+ = m/z 624.3226 and (M+2H) 2+ = m/z 806.8999, respectively, with 10 p.p.m. mass tolerance and retention time within 60 s. Peaks of y-type fragment ions from both peptides were identified by searching corresponding m/z values with the same criteria and retention time based on the analysis of the recombinant scFv or antibody. ICIS integration algorithm was used to detect and integrate the area of each peak. The summed areas of all peaks (6 y-type ions) associated with EH12/2H7 peptide and E27 scFv peptide from each time point (6, 24 and 48 h) were calculated separately then plotted by time point using Prism. Chromatograms of untreated and scFv i.v. samples were integrated and plotted using the same method.
Statistical analysis. Log-rank, unpaired or paired t tests were performed using GraphPad Prism 7 software) where appropriate.
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
